SCHEMBL3010244

SCHEMBL3010244

CC1=C(C(=O)O)C(c2ccccc2-c2ccc(C(F)(F)F)cc2)n2nnnc2N1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.54
MAPT P10636 3/20 0.53
ALDH1A1 P00352 10/20 0.52
LMNA P02545 3/20 0.50
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TP53 P04637 1/20 0.48
KMT2A Q03164 2/20 0.47
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258306 0.85 ALDH1A1 (0.51) THRBMAPTALDH1A1LMNAGAA
SCHEMBL2992365 0.85 ALDH1A1 (0.51) THRBMAPTALDH1A1LMNAGAA
SCHEMBL3003897 0.82 ALDH1A1 (0.52) THRBMAPTALDH1A1LMNAGAA
SCHEMBL3250826 0.79 ALDH1A1 (0.58) THRBMAPTALDH1A1LMNAGAA
SCHEMBL3004302 0.79 KMT2A (0.52) THRBMAPTALDH1A1LMNAGAA
SCHEMBL3006646 0.79 NPSR1 (0.57) THRBMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL3000251 0.79 ALDH1A1 (0.48) THRBMAPTALDH1A1LMNAGAA
SCHEMBL2999799 0.78 ALDH1A1 (0.53) THRBMAPTALDH1A1LMNAGAA
SCHEMBL2992225 0.77 ALDH1A1 (0.58) THRBMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL2993898 0.77 ALDH1A1 (0.56) THRBMAPTALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
WO-2010002483-A1 OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2010-01-07 WO disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
WO-2009006580-A1 OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R THRB 1655/4885MAPT 4314/4885ALDH1A1 274/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R THRB 1655/4885MAPT 4314/4885ALDH1A1 274/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R THRB 1655/4885MAPT 4314/4885ALDH1A1 274/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R THRB 1655/4885MAPT 4314/4885ALDH1A1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.